HeartWare dives on big Q1 sales, earnings misses
Shares prices for HeartWare International (NSDQ:HTWR) plunged this morning after the implantable heart pump maker posted 1st-quarter earnings that badly missed expectations on Wall Street. Framingham, Mass.-based HeartWare reported that losses widened 20.1% to -$17.5 million, or -$1 per share, on a -21.3% revenue slide to $55.1 million. Adjusted to exclude 1-time items, losses per share were -95¢, -16¢ off the forecast on The Street, where analysts were looking for sales of $59.9 million. “In the 1st quarter, our international revenue performance was impacted by competitive dynamics in Germany, as well as lower implant volumes in certain other international markets,” president &CEO Doug Godshall said in prepared remarks. “In the U.S., the bridge-to-transplant segment of the market for which the HVAD system is approved, showed softness resulting from a slowdown in the volume of patients eligible for bridge-to-transplant procedures at the start of the year and an evolving trend toward destination therapy due to ease of reimbursement. Our 1st-quarter financial performance and the overall market dynamics reinforce the importance of our work toward securing a DT indication in the U.S. and focusing our energies upon the continued enhancement of our technologies. “Despite 1st-quarter trends, the HVAD system remains the most versatile pump, utilized in the widest range of patients, among currently available ventricular as...
ConclusionPatients who are at risk for SCA are patients who have had a cardiac arrest due to ventricular fibrillation (VF) or sustained ventricular tachycardia (SVT), those with familial or inherited condition with sudden cardiac arrest risk, myocardial infarction with an ejection fraction (EF) of less than or equal to 35%, dilated cardiomyopathy (including NICM), with an EF of less than or equal to 35%, ICD explanations, and other conditions with high risk of ventricular tachycardia (VT) or VF are candidates for the WCD.The sample of data was from 186 patients. However, more patients were likely candidates but may not hav...
Yasmin Swift, 19, from Ashford, Kent, needs a double lung and heart transplant after being diagnosed with idiopathic pulmonary arterial hypertension in November last year.
Reported ventricular assist device (VAD) experience in the pediatric congenital heart disease (CHD) population is limited. We sought to describe contemporary use and outcomes of VADs in children with CHD and compare outcomes to children without CHD.
Chronic lung allograft dysfunction (CLAD) is the principal obstacle to improved long-term survival after lung transplantation.1 CLAD is a condition of sustained lung function impairment recognized by a persistent decline in the forced expiratory volume in one second (FEV1) relative to the highest posttransplant baseline after exclusion of confounding conditions.2,3 Previously bronchiolitis obliterans syndrome (BOS) was the most widely described CLAD phenotype; however, accumulating evidence suggests CLAD takes on at least two phenotypes conferring distinct prognoses.
In conclusion, there was no clear benefit of using multidrug regimen as it did not impact infection-free survival or all-cause mortality compared with single-drug regimen. Prospective clinical trials are needed to further define the optimal SIP regimen for LVAD implantation.
We present the anesthetic management of a patient who was diagnosed with bilateral neuroendocrine tumors soon after heart-lung transplantation and underwent successful staged bilateral adrenalectomy.
Lymphangioleiomyomatosis (LAM) is a rare disease of women. Decline in lung function is variable, making appropriate targeting of therapy difficult. We used unbiased serum proteomics to identify markers associated with outcome in LAM. 101 women with LAM and 22 healthy controls were recruited from the National Centre for LAM in the UK. 152 DNA and serum samples with linked lung function and outcome data were obtained from patients in the National Heart, Lung and Blood Institute LAM Registry in the USA. Proteomic analysis was performed on a discovery cohort of 50 LAM and 20 control serum samples using a SCIEX SWATH mass spect...
Ventricular assist devices (VADs) are currently standard therapy for patients with advanced heart failure that is refractory to medical therapy.1 VADs can be categorized as pulsatile flow VADs (PF-VADs) and continuous flow VADs (CF-VADs). Both PF-VADs and CF-VADs are similarly effective in providing hemodynamic benefit (augmenting cardiac output and end-organ perfusion, and reducing ventricular work), and improving the quality of life and functional capacity of patients.2,3 CF-VADs are preferred over the PF-VADs due to advantages including compact size, reliability, energy efficiency, ease of implantation, and operation.
Contributors : Thomas M Egan ; Masharn Doanes ; J P Jin ; Scott RandellSeries Type : Expression profiling by arrayOrganism : Rattus norvegicusIschemia-reperfusion injury (IRI) is a major cause of morbidity and mortality following conventional lung transplantation and warm ischemia may limit success of transplanting lungs from non-heart-beating donors. We sought to determine alterations in gene expression in rat lung tissue subjected to warm ischemia in vivo followed by reperfusion.Keywords: time course
Since 2012, there has been growing use of the HeartWare (Medtronic, Mounds View, MN) intracorporeal continuous flow (CF) ventricular assist device (VAD) in children, despite it not being labeled for use in pediatric patients. We sought to describe the use and outcomes of children with HeartWare VADs.